It’s wonderful what happens when a real expert gets stuck into a question. Back in November, Luigi briefly blogged a story about pharmaceutical researchers who derived some inspiration from gorillas and their liking for a particular plant. In the comments, Kathryn Garforth Mitchell wondered about the access and benefit sharing aspects of the story. Luigi, characteristically, had no idea, feared for the worst, and hoped he was wrong. Well, maybe his hopes were not in vain, because Kathryn has spent the past four months ferreting out the details and piecing most of the story together. The result is an illuminating series of posts that shows just how complex arrangements can be. I’m not going to link to all four of them; you should start at number one — Gorilla medicine: a complex web — and work your way through them.
One interesting point of direct relevance. Scientists in the US say that they may source the active compounds from plants grown locally in Nigeria or Ghana. This is very atypical of pharmaceutical arrangements, which usually involve discovering the active ingredient in a plant and then synthesizing it chemically. It is also, perhaps, the biggest source of confusion for those interested in access and benefit sharing of specifically agricultural products. While genes may be discovered in farmer varieties and wild relatives, the value of those genes never derives from the manufacture of the gene’s products.